Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Eguchi Eye Hospital, Hokkaido, Japan.
Ophthalmology. 2017 Apr;124(4):519-523. doi: 10.1016/j.ophtha.2016.12.010. Epub 2017 Jan 19.
To report the results of a clinical investigation after an outbreak of subacute-onset toxic anterior segment syndrome (TASS) after implantation of single-piece acrylic intraocular lenses (IOLs), which then were recalled voluntarily from the market.
Retrospective, multicenter, observational case series.
Cases reported to the manufacturer from January 2015 through March 2016 of unusual ocular inflammation after cataract surgery using AcrySof ReSTOR, ReSTOR toric, or AcrySof IQ toric SN6AT6-9 IOLs (Alcon Laboratories, Inc., Fort Worth, TX).
The independent investigation committee, not Alcon, directly requested the surgeons for data on 304 eyes from 184 facilities.
Consent for data collection was obtained for 201 eyes from 130 facilities. By excluding cases with infectious endophthalmitis and inconclusive cases, the investigation committee identified 147 cases of subacute-onset TASS. AcrySof ReSTOR or ReSTOR toric IOLs and AcrySof IQ toric SN6AT6-9 IOLs were implanted in 94 eyes (63.9%) and 53 eyes (36.1%), respectively. The mean onset time was 13.1±16.4 days after surgery (range, 1-88 days), with 84 eyes (57.1%) demonstrating symptoms within 7 days after surgery. Typical clinical symptoms were mild to moderate exacerbation of inflammation in the anterior chamber after an uneventful clinical course for a few days after surgery. One hundred four eyes (70.7%) were treated with medication alone, and 43 eyes (29.3%) underwent surgery, including irrigation of the anterior chamber, vitrectomy, and removal of the IOL. The mean best-corrected visual acuity (BCVA) at the final visit (-0.012±0.175 logarithm of the minimum angle of resolution [logMAR]) was significantly better than the BCVA at the onset of TASS (0.158±0.351 logMAR) and did not differ from that before inflammation developed (-0.004±0.162 logMAR). Overall treatment outcomes were favorable.
A large-scale outbreak of subacute-onset TASS developed after implantation of a specific model of IOL.
报告因植入一体式丙烯酸人工晶状体(IOL)后发生亚急性发作性前节毒性综合征(TASS)而导致的市场召回事件后的临床调查结果。
回顾性、多中心、观察性病例系列研究。
自 2015 年 1 月至 2016 年 3 月,有病例报告称在白内障手术后使用 AcrySof ReSTOR、ReSTOR toric 或 AcrySof IQ toric SN6AT6-9 IOL(Alcon Laboratories, Inc., Fort Worth,TX)后出现异常眼内炎症。
独立调查委员会而非 Alcon 公司直接向 184 家机构的外科医生请求提供 304 只眼的数据。
对来自 130 家机构的 201 只眼进行了数据收集同意。排除感染性眼内炎和不确定病例后,调查委员会确定了 147 例亚急性发作性 TASS。94 只眼(63.9%)植入了 AcrySof ReSTOR 或 ReSTOR toric IOL,53 只眼(36.1%)植入了 AcrySof IQ toric SN6AT6-9 IOL。手术 13.1±16.4 天后(范围为 1-88 天)出现平均发病时间,84 只眼(57.1%)在术后 7 天内出现症状。典型的临床症状是手术后几天内前房炎症轻度至中度加重,在此之前临床过程平稳。104 只眼(70.7%)单独接受药物治疗,43 只眼(29.3%)接受手术治疗,包括前房冲洗、玻璃体切除术和 IOL 取出。末次随访时最佳矫正视力(BCVA)平均值(-0.012±0.175 最小分辨角对数 [logMAR])明显优于 TASS 发病时的 BCVA(0.158±0.351 logMAR),且与炎症发生前的 BCVA 无差异(-0.004±0.162 logMAR)。总体治疗效果良好。
一种特定型号的 IOL 植入后发生了大规模的亚急性发作性 TASS 爆发。